Skip to main content

MOMs (CTN-0080)

The primary objective of the Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs) Study is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release (XR) buprenorphine (BUP), compared to sublingual (SL) BUP, on mother and infant outcomes. The primary hypotheses are that the BUP-XR, relative to the BUP-SL, group will have significantly: 1) less illicit opioid use during pregnancy; 2) shorter infant hospital length of stay (LOS); and 3) greater postpartum BUP adherence. Testing conceptual models of the mechanisms by which BUP-XR may improve mother-infant outcomes, relative to BUP-SL, is a secondary trial objective. Determining the economic value of BUP-XR, compared to BUP-SL, to treat OUD in pregnant women is a tertiary objective.

Study Team